Sofinnova Investments related stories
All articles and analysis
VC-backed Entasis Therapeutics debuts IPOWaltham, Massachusetts-based Entasis Therapeutics, a biopharmaceutical company focused on developing new antibacterial products, has raised about $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading September 26, 2018 on the NASDAQ under the ticker symbol "ETTX." Credit Suisse and BMO Capital Markets are the lead underwriters. Entasis' pre-IPO backers include Pivotal bioVenture Partners, Sofinnova Ventures and TPG Biotech.
- VC-backed Neurana Pharmaceuticals recruits Thompson as president and CEO
Neurana Pharmaceuticals Inc, a specialty pharmaceutical company focused on treating neuromuscular conditions, has appointed Craig Thompson as president and CEO. Previously, Thompson worked at Anthera Pharmaceuticals where he was president and CEO. Neurana's backers include Sofinnova Ventures, New Leaf Venture Partners, H.I.G. BioHealth Partners, Longitude Capital and MagnaSci Ventures.
- Samsara BioCapital raises $310 mln for venture-capital fund
Samsara BioCapital has raised $310 million for a venture-capital fund, according to a filing with the SEC.
- Samsara BioCapital raises $260.6 mln for venture capital fund
Samsara BioCapital has raised $260.6 million toward a $300 million venture-capital fund, according to a filing with the SEC.
